2023年5月31日

发布的新闻记者Glyscend疗法背线数据的聚合物针对2型糖尿病和肥胖的今天,希望候选人的减肥手术相同的效果没有并发症的侵入性的标准程序。口服gut-targeting聚合物,称为g - 200,和临床相关的减少葡萄糖后饮食和体重和减少食物摄入量的51参与公司的活动花絮阶段试验。病人把聚合物或安慰剂连续14天每天两次。继续阅读端点免费订阅立即解锁这个故事,加入170400 +生物制药专业人士每天阅读端点,它是免费的。报名副编辑作为字符串初创公司的目标是创造新的基因疗法治疗没有首选穿梭AAV病毒的方法,和多个基因编辑生物技术做相同的,这样一个创业公司即将关闭。求和生物,由至少2400万美元的系列基金,是“终止操作”下个月,每一个员工的LinkedIn的资料更新。(根据他们的LinkedIn档案,一名员工说,该公司筹集了6000万美元。)另一位员工走上社交网站上周说的情况是“不可逾越的”,他指出“尽管全力和错误执行,科学,这一次,是难以捉摸的。“继续阅读端点免费订阅立即解锁这个故事,加入170400 +生物制药专业人士阅读每日端点,它是免费的。注册高级编辑FDA实施临床抓住PepGen印第安纳州的药物肌强直性营养不良1型(DM1),减慢公司的计划将第二个神经肌肉计划到诊所。PepGen没有具体说明是什么引起了关注,只是说FDA在30天内将提供一个正式的信说背后的原因。 Spun out of Oxford University and backed by RA Capital, PepGen specializes in oligonucleotides — short strands of synthetic RNA or DNA molecules — that it delivers with special cell-penetrating peptides. By conjugating the peptides with oligonucleotides, the biotech promises to improve the uptake and activity of the resulting therapy. Keep reading Endpoints with a free subscription Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor While one of its main bets on multiple sclerosis is stuck in a year-long partial clinical hold, Sanofi has new mid-stage data on another investigational MS therapy that the company says lay the groundwork for pivotal trials next year. On Wednesday, the French pharma said its investigational drug frexalimab was better than placebo at reducing certain types of brain lesions as observed by MRI at week 12. The study included 129 people with relapsing multiple sclerosis. Keep reading Endpoints with a free subscription Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Associate Editor Rain Oncology will let go 65% of its workers, stop enrolling patients in a basket trial and nix plans for another study of its sole asset following a Phase III failure last week. The Newark, CA-based biotech had about 70 employees at the time of the data last week, meaning about 40 to 50 staffers will be affected by the layoffs, CEO and co-founder Avanish Vellanki said in an emailed statement to Endpoints News. That includes medical chief Richard Bryce, who will hand his duties to Robert Doebele, Rain’s co-founder, president and chief scientific officer, the biotech said in a press release announcing the news Tuesday. Keep reading Endpoints with a free subscription Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Editor Eli Lilly will pay $13.5 million and continue to cap out-of-pocket insulin costs at $35 per month for the next four years in what plaintiffs called an “icebreaker” class settlement to a years-long drug pricing suit. Insulin users filed suit against Eli Lilly, Novo Nordisk and Sanofi in 2017, accusing the drugmakers of “artificial and fraudulent inflation” of their insulin prices in the US. In an amended complaint filed in 2021, plaintiffs alleged the companies raised their list prices “in perfect lockstep” by more than 150% over a five-year period. Keep reading Endpoints with a free subscription Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free. SIGN UP